Eliana Merle
Stock Analyst at Barclays
(3.27)
# 903
Out of 5,182 analysts
114
Total ratings
42.35%
Success rate
4.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Neutral | $36 → $45 | $47.30 | -4.86% | 11 | May 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $923 → $917 | $709.21 | +29.30% | 2 | Apr 30, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $106 → $115 | $75.48 | +52.36% | 2 | Apr 30, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $44 → $43 | $24.82 | +73.25% | 1 | Apr 29, 2026 | |
| INSM Insmed | Maintains: Overweight | $231 → $237 | $140.01 | +69.27% | 2 | Apr 1, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $24 → $41 | $40.97 | +0.07% | 10 | Apr 1, 2026 | |
| QURE uniQure | Maintains: Equal-Weight | $31 → $25 | $20.68 | +20.89% | 6 | Mar 23, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $55.46 | +89.33% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $45.03 | +24.36% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.35 | -14.59% | 5 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $606 → $607 | $429.85 | +41.21% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $35.14 | +67.90% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $8 | $7.90 | +1.27% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $68 → $119 | $65.52 | +81.62% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $66 | $29.47 | +123.96% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $518.66 | +85.86% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.28 | +241.23% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $228.94 | +49.38% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.46 | +248.84% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $68.99 | +15.96% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $297.93 | +76.89% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.02 | +694.70% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $69.78 | -71.34% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $22.04 | -45.55% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $1.89 | +324.40% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $10.77 | +95.08% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $83.59 | -16.26% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $4.00 | -45.00% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $147.90 | -51.99% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $99.35 | +31.86% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $42.26 | -88.17% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $52.96 | -66.01% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $19.56 | +12.50% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $9.39 | +400.53% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $28.43 | +371.38% | 3 | Aug 19, 2020 |
Moderna
May 4, 2026
Maintains: Neutral
Price Target: $36 → $45
Current: $47.30
Upside: -4.86%
Regeneron Pharmaceuticals
Apr 30, 2026
Maintains: Overweight
Price Target: $923 → $917
Current: $709.21
Upside: +29.30%
Ionis Pharmaceuticals
Apr 30, 2026
Maintains: Overweight
Price Target: $106 → $115
Current: $75.48
Upside: +52.36%
Ultragenyx Pharmaceutical
Apr 29, 2026
Maintains: Overweight
Price Target: $44 → $43
Current: $24.82
Upside: +73.25%
Insmed
Apr 1, 2026
Maintains: Overweight
Price Target: $231 → $237
Current: $140.01
Upside: +69.27%
Apellis Pharmaceuticals
Apr 1, 2026
Maintains: Equal-Weight
Price Target: $24 → $41
Current: $40.97
Upside: +0.07%
uniQure
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $20.68
Upside: +20.89%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $55.46
Upside: +89.33%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $45.03
Upside: +24.36%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.35
Upside: -14.59%
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $429.85
Upside: +41.21%
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $35.14
Upside: +67.90%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $7.90
Upside: +1.27%
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $65.52
Upside: +81.62%
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $29.47
Upside: +123.96%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $518.66
Upside: +85.86%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $5.28
Upside: +241.23%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $228.94
Upside: +49.38%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.46
Upside: +248.84%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $68.99
Upside: +15.96%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $297.93
Upside: +76.89%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.02
Upside: +694.70%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $69.78
Upside: -71.34%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $22.04
Upside: -45.55%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $1.89
Upside: +324.40%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $10.77
Upside: +95.08%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $83.59
Upside: -16.26%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $4.00
Upside: -45.00%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $147.90
Upside: -51.99%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $99.35
Upside: +31.86%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $42.26
Upside: -88.17%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $52.96
Upside: -66.01%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $19.56
Upside: +12.50%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $9.39
Upside: +400.53%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $28.43
Upside: +371.38%